Torsten Falk

Research Professor

Professor, Neuroscience - GIDP

Professor, Physiological Sciences - GIDP

Member of the Graduate Faculty

Research Professor, Pharmacology

Life Sciences North, 359

Dr. Falk is a Professor of Neurology and of Pharmacology, and he is the Director of the Preclinical Parkinson's disease Laboratory. He has received his PhD from the University of Hamburg, Germany. Dr. Falk is the author of over 45 peer-reviewed journal publications, with an h-index of 24, an I-10-index of 35, and over 160 peer-reviewed abstracts and conference presentations. He holds two patents and his work has led to ongoing Clinical trials testing a novel treatment for levodopa-induced dyskinesias. He is also Co-founder and equity partner in Teleport Pharmaceuticals, LLC. He is a standing member of the NIH Clinical Neurotransmitters and Neuroplasticity (CNNT) study section. He is an ad hoc reviewer for the Michael J. Fox Foundation for Parkinson's Research, as well as the Cure Parkinson's and Parkinson's UK Foundations. He has been a Member of the Grant Review Committee for the Parkinson's Foundation (PF).

Research Interest

Dr. Falk's research focuses on cellular and rodent models to test 1) novel pharmacological treatments for levodopa-induced dyskinesias, a major side effect of Parkinson’s disease treatment, 2) novel neuroprotective (growth factor mediated) gene therapy approaches to Parkinson’s disease, and 3) development of glycopeptides for the treatment of Parkinson’s disease and other neurological conditions.

Offering Research Opportunities

Yes

Prerequisite Courses

None

Majors Considered

All

Types of Opportunities

For credit

Description of Opportunity

No description given

Start Date

January 2024